Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial
By
Sebastian Wolf
Youxin Chen
Xiaorong Li
Masahiko Shimura
Taiji Sakamoto
Charles C. Wykoff
Andres Emanuelli
Hani Salehi-Had
Kang Yan
Lidija Kovacic
Yongsoo Kim
June 1, 2026
Clinical Scorecard: Efficacy of Brolucizumab for Proliferative Diabetic Retinopathy: Insights from the CONDOR Randomized Clinical Trial
At a Glance
Category Detail
Condition Proliferative Diabetic Retinopathy Key Mechanisms Pathologic neovascularization driven by upregulation of VEGF due to hyperglycemia and retinal ischemia. Target Population Adults with diabetes type 1 or 2 and proliferative diabetic retinopathy without previous PRP treatment. Care Setting Multicenter, randomized clinical trial
Key Highlights
Brolucizumab is a high-affinity anti-VEGF therapy with a low molecular weight. The CONDOR study is a phase 3 trial comparing brolucizumab to panretinal laser photocoagulation. Participants were randomized 1:1 to receive either brolucizumab or PRP. Brolucizumab treatment involves initial doses every 6 weeks, followed by maintenance every 12 weeks. Key exclusion criteria included center-involved diabetic macular edema and previous PRP. Guideline-Based Recommendations
Diagnosis
Diagnosis of PDR confirmed by standard or widefield color fundus photography and fluorescein angiography. Management
Brolucizumab or PRP as treatment options for PDR. Monitoring & Follow-up
Visual acuity and disease activity should be monitored throughout treatment. Risks
Potential complications of PRP include choroidal effusions and visual field deficits. Patient & Prescribing Data
Adults aged 18 years or older with diabetes and PDR.
Brolucizumab may offer additional efficacy beyond existing anti-VEGF therapies.
Clinical Best Practices
Ensure informed consent is obtained prior to study-related procedures. Follow CONSORT guidelines for reporting clinical trials. Mask site personnel performing visual assessments to maintain study integrity. Related Resources & Content
